DiaMedica Therapeutics Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+3.31%
vs ±15.9% implied · ×0.21
shaded = implied · ▲▼ = realized
No other changes.
No other changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of DiaMedica Therapeutics Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of DiaMedica Therapeutics Inc.'s 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Mar 30 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 30 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
DiaMedica Therapeutics Inc.
9.96
pre 10.45 +4.50%
No trades yet today.
No trades yet today.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Manager | Value | % base | |
|---|---|---|---|
| Cooperman Leon G | $24.3M | 27.70% | +70.79% |
| BlackRockindex-like | $15.9M | 18.08% | +21.34% |
| Geodeindex-like | $6.3M | 7.18% | +14.55% |
| Millennium | $6.0M | 6.79% | −9.65% |
| State Streetindex-like | $4.6M | 5.19% | +0.39% |
| Manager | Value | % base | |
|---|---|---|---|
| Cooperman Leon G | $24.3M | 27.70% | +70.79% |
| BlackRockindex-like | $15.9M | 18.08% | +21.34% |
| Geodeindex-like | $6.3M | 7.18% | +14.55% |
| Millennium | $6.0M | 6.79% | −9.65% |
| State Streetindex-like | $4.6M | 5.19% | +0.39% |
Largest filed tie
—
Bull2
Bear1
Expected move
No implied move.